Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for William M. Vaughn, III.�
13.44
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.31 - 14.07
Open     -
Vol / Avg. 0.00/731,717.00
Mkt cap 641.93M
P/E 18.43
Div/yield     -
EPS 0.73
Shares 47.76M
Beta     -
Inst. own 89%
Aug 10, 2015
Q2 2015 Supernus Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 2, 2015
Supernus Pharmaceuticals Inc at Jefferies Global Healthcare Conference - 2:00PM EDT - Add to calendar
May 21, 2015
Supernus Pharmaceuticals Inc Annual Shareholders Meeting
May 6, 2015
Q1 2015 Supernus Pharmaceuticals Inc Earnings Call - Webcast
May 5, 2015
Q1 2015 Supernus Pharmaceuticals Inc Earnings Release
Mar 11, 2015
Q4 2014 Supernus Pharmaceuticals Inc Earnings Call - Webcast
Mar 10, 2015
Q4 2014 Supernus Pharmaceuticals Inc Earnings Release
Mar 4, 2015
Supernus Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 3.26% 16.28%
Operating margin 4.61% 17.73%
EBITD margin - 20.61%
Return on average assets 2.65% 15.99%
Return on average equity 4.43% 37.92%
Employees 309 -
CDP Score - -

Address

1550 East Gude Drive
ROCKVILLE, MD 20850
United States - Map
+1-301-8382500 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Supernus Pharmaceuticals, Inc. (Supernus) is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s neurology portfolio consists of Oxtellar XR (extended release oxcarbazepine) and Trokendi XR (extended release topiramate) and topiramate products, respectively, indicated for epilepsy in the United States market. Oxtellar XR and Trokendi XR are novel extended release formulations of two well-known and approved AEDs, oxcarbazepine and topiramate. The Company is also developing multiple product candidates in psychiatry to address the treatment of attention deficit hyperactivity disorder (ADHD), including ADHD patients with impulsive aggression.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 58
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D., Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 57
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Charles W. Newhall III Independent Director
Age: 70
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 62
Bio & Compensation  - Reuters